{"id":50266,"date":"2022-10-31T14:02:13","date_gmt":"2022-10-31T13:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-market-report-2022-high-prevalence-of-chronic-neuropathic-pain-fuels-growth-researchandmarkets-com\/"},"modified":"2022-10-31T14:02:13","modified_gmt":"2022-10-31T13:02:13","slug":"global-peripheral-neuropathy-market-report-2022-high-prevalence-of-chronic-neuropathic-pain-fuels-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-market-report-2022-high-prevalence-of-chronic-neuropathic-pain-fuels-growth-researchandmarkets-com\/","title":{"rendered":"Global Peripheral Neuropathy Market Report 2022: High Prevalence of Chronic Neuropathic Pain Fuels Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Peripheral Neuropathy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nGeneral population studies have reported that 7 to 8% adults currently have chronic neuropathic pain, where the reported incidence is of 8 cases per 1,000 individuals per year. In the U.K. alone, 26% individuals with diabetes experience peripheral neuropathic pain. Globally, this figure translates to approximately 50 million individuals, which will further increase as is anticipated that the prevalence of diabetes will grow to an estimated 4.4% by 2030.\n<\/p>\n

\nAnticonvulsant pregabalin (Lyrica, Pfizer) is among the most widely spread drug for neuropathic pain. Drug manufacturers and developers are thus required to demonstrate improved efficacy to patients while simultaneously report cost-benefit to insurers and regulatory bodies. In terms of market competition, the existing brands are being continually expanded across geographies. Commercialization of pipeline entities into the market will somewhat offset generic erosion.\n<\/p>\n

\nThe report offers strategic insights into the overall Peripheral Neuropathy market along with the market size and estimates for the duration 2022 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of treatment and different geographies. The drug types studied for analyzing the overall global peripheral neuropathy market are segmented into pharmacological therapies and non-pharmacological therapies. Pharmacological therapies includes pain reliever, anti-seizure medication, antidepressants. Non Pharmacological therapies transcutaneous electrical nerve stimulation, plasma exchange and intravenous immune globulin and others (physical therapy and surgery).\n<\/p>\n

\nPharmacological therapies most commonly used and dominates the peripheral neuropathy market, while non-pharmacological therapies are used along with other treatment options. Anti-seizure medications occupies maximum share in peripheral market around 41% in 2016, followed by antidepressants and pain killers. Anti-seizure medication include Gabapentin and Pregabalin, that are used as first line of treatment, with Pregabalin occupying major share. Among antidepressants, Amitriptyline is widely recommended for neuropathic pain and thus dominates the peripheral neuropathy antidepressant market.\n<\/p>\n

\nAt present, North America was observed as the largest market for peripheral neuropathy. The rising geriatric population, growing incidences of diabetes in the region is the prime factor driving the North America peripheral neuropathy market. U.S. held the largest share in North America due to factors such as developed healthcare infrastructure, major pharmaceutical giants based in the country, high research trials on peripheral neuropathy in the country and high prices of the medication generating high revenue. Asia Pacific would exhibit the fastest growth rate in the Global Peripheral Neuropathy market due to aging population, increasing health awareness and high prevalence of the diabetes, cancer and HIV\/AIDS.\n<\/p>\n

\nMarket Segmentation<\/strong>\n<\/p>\n

\nTreatment Type<\/strong>\n<\/p>\n